The difference in mean costs as a pharmacoeconomic outcome variable: power considerations.

Bouckaert, André;Crott, Ralph
(1997) Controlled Clinical Trials — Vol. 18, n° 1, p. 58-64 (1997)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 439.97 KB
Request a copy

Details

Authors
  • Bouckaert, AndréUCLouvain
    Author
  • Crott, RalphUCLouvain
    Author
Abstract
The difference in mean costs between a placebo and a drug treated group is used for the pharmacoeconomic evaluation of a new drug. The distribution of costs without treatment (null hypothesis) is determined through hospital records. The sampling properties are established by simulation. The results of the simulation allow determination of a break point of differences corresponding to a given level of significance. For power determination, using this break point, clinical hypotheses are used to generate the distribution of costs under treatment (alternative hypothesis).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bouckaert, A., & Crott, R. (1997). The difference in mean costs as a pharmacoeconomic outcome variable: power considerations. Controlled Clinical Trials, 18(1), 58-64. https://doi.org/10.1016/S0197-2456(95)00258-8 (Original work published 1997)